Proprietary Autologous Cell Therapies: Their core products, MACI and Epicel, utilize the patient's own cells, leading to excellent biological compatibility and reduced immune response, offering a unique and highly effective treatment approach.

Specialized Manufacturing Expertise: Operating state-of-the-art, GMP-compliant facilities for complex autologous cell expansion and tissue engineering creates a significant barrier to entry for competitors.

Strong Regulatory Approvals & Exclusivity: Products like MACI, Epicel (with Orphan Drug Designation), and NexoBrid hold specific FDA approvals for critical indications, providing market access and, in some cases, exclusivity.